• 1
    Cutler JE, Deepe GS Jr, Klein BS. Advances in combating fungal diseases: vaccines on the threshold. Nat Rev Microbiol 2007;5:1328.
  • 2
    Han Y, Cutler JE. Antibody response that protects against disseminated candidiasis. Infect Immun 1995;63:27149.
  • 3
    Han Y, Riesselman MH, Cutler JE. Protection against candidiasis by an immunoglobulin G3 (IgG3) monoclonal antibody specific for the same mannotriose as an IgM protective antibody. Infect Immun 2000;68:164954.
  • 4
    Han Y, Morrison RP, Cutler JE. A vaccine and monoclonal antibodies that enhance mouse resistance to Candida albicans vaginal infection. Infect Immun 1998;66:57716.
  • 5
    Han Y, Kanbe T, Cherniak R, Cutler JE. Biochemical characterization of Candida albicans epitopes that can elicit protective and nonprotective antibodies. Infect Immun 1997;65:41007.
  • 6
    Han Y, Kozel TR, Zhang MX, MacGill RS, Carroll MC, Cutler JE. Complement is essential for protection by an IgM and an IgG3 monoclonal antibody against experimental, hematogenously disseminated candidiasis. J Immunol 2001;167:15507.
  • 7
    Han Y, Cutler JE. Assessment of a mouse model of neutropenia and the effect of an anti-candidiasis monoclonal antibody in these animals. J Infect Dis 1997;175:116975.
  • 8
    Shibata N, Suzuki A, Kobayashi H, Okawa Y. Chemical structure of the cell-wall mannan of Candida albicans serotype A and its difference in yeast and hyphal forms. Biochem J 2007;404:36572.
  • 9
    Shibata N, Ikuta K, Imai T et al. Existence of branched side chains in the cell wall mannan of pathogenic yeast, Candida albicans. Structure-antigenicity relationship between the cell wall mannans of Candida albicans and Candida parapsilosis. J Biol Chem 1995;270:111322.
  • 10
    Kobayashi H, Shibata N, Nakada M et al. Structural Study of Cell-Wall Phosphomannan of Candida-Albicans Nih-B-792 (Serotype-B) Strain, with Special Reference to H-1 and C-13 Nmr Analyses of Acid-Labile Oligomannosyl Residues. Arch Biochem Biophys 1990;278:195204.
  • 11
    Shibata N, Akagi R, Hosoya T et al. Existence of novel branched side chains containing beta-1,2 and alpha-1,6 linkages corresponding to antigenic factor 9 in the mannan of Candida guilliermondii. J Biol Chem 1996;271:925966.
  • 12
    Kobayashi H, Tanaka S, Suzuki J et al. Amended structure of side chains in a cell wall mannan from Candida albicans serotype A strain grown in yeast extract-Sabouraud liquid medium under acidic conditions: detection of the branched side chains corresponding to antigenic factor 4. FEMS Microbiol Lett 1997;152:23542.
  • 13
    Paulovicova L, Bystricky S, Paulovicova E, Karelin AA, Tsvetkov YE, Nifantiev NE. Model alpha-mannoside conjugates: immunogenicity and induction of candidacidal activity. FEMS Immunol Med Microbiol 2010;58:30713.
  • 14
    Paulovicova L, Paulovicova E, Karelin AA, Tsvetkov YE, Nifantiev NE, Bystricky S. Humoral and cell-mediated immunity following vaccination with synthetic Candida cell wall mannan derived heptamannoside-protein conjugate: immunomodulatory properties of heptamannoside-BSA conjugate. Int Immunopharmacol 2012;14:17987.
  • 15
    Chernyak A, Karavanov A, Ogawa Y, Kovac P. Conjugating oligosaccharides to proteins by squaric acid diester chemistry: rapid monitoring of the progress of conjugation, and recovery of the unused ligand. Carbohydr Res 2001;330:47986.
  • 16
    Karelin AA, Tsvetkov YE, Paulovicova L, Bystricky S, Paulovicova E, Nifantiev NE. Synthesis of 3,6-branched oligomannoside fragments of the mannan from Candida albicans cell wall corresponding to the antigenic factor 4. Carbohydr Res 2010;345:128390.
  • 17
    Peat S, Whelan WJ, Edwards TE. 6. Polysaccharides of baker's yeast. Part IV. Mannan. J Chem Soc (Resumed) 1961;00:2934.
  • 18
    Libjakova L, Bystricky S, Lizicarova I, Paulovicova E, Machova E. Evaluation of different mannan polysaccharide usage in enzyme-linked immunosorbent assay for specific antibodies determination. J Pharm Biomed Anal 2007;45:5215.
  • 19
    Paulovicova E, Bystricky S, Masarova J, Machova E, Mislovicova D. Immune response to Saccharomyces cerevisiae mannan conjugate in mice. Int Immunopharmacol 2005;5:16938.
  • 20
    Paulovicova E, Korcova J, Farkas P, Bystricky S. Immunological efficacy of glycoconjugates derived from Vibrio cholerae O1 serotype Ogawa detoxified LPS in mice. J Med Microbiol 2010;59:14408.
  • 21
    Soloviev DA, Fonzi WA, Sentandreu R, et al. Identification of pH-regulated antigen 1 released from Candida albicans as the major ligand for leukocyte integrin alphaMbeta2. J Immunol 2007;178:203846.
  • 22
    Low CY, Rotstein C. Emerging fungal infections in immunocompromised patients. F1000 Med Rep 2011;3:14.
  • 23
    Trick WE, Fridkin SK, Edwards JR, Hajjeh RA, Gaynes RP, Surveil NNI. Secular trend of hospital-acquired candidemia among intensive care unit patients in the United States during 1989-1999. Clin Infect Dis 2002;35:62730.
  • 24
    Wisplinghoff H, Bischoff T, Tallent M, Seifert H, Wenzel RP, Edmond MB. Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study. (vol 39, pg 309, 2004). Clin Infect Dis 2004;39:1093.
  • 25
    Pappas PG, Rex JH, Lee J, et al. A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients. Clin Infect Dis 2003;37:63443.
  • 26
    Purkerson J, Isakson P. A 2-Signal Model for Regulation of Immunoglobulin Isotype Switching. FASEB J 1992;6:324552.
  • 27
    Haaheim LR, Jonsson R. Rapid quality evaluation of hybridomas using ELISPOT and cell-ELISA techniques. Immunol Lett 1992;34:13542.
  • 28
    Andraud M, Lejeune O, Musoro JZ, Ogunjimi B, Beutels P, Hens N. Living on three time scales: the dynamics of plasma cell and antibody populations illustrated for hepatitis a virus. PLoS Comput Biol 2012;8:e1002418.
  • 29
    Slifka MK, Ahmed R. Long-lived plasma cells: a mechanism for maintaining persistent antibody production. Curr Opin Immunol 1998;10:2528.
  • 30
    Kumamoto CA, Vinces MD. Contributions of hyphae and hypha-co-regulated genes to Candida albicans virulence. Cell Microbiol 2005;7:154654.
  • 31
    Whiteway M, Oberholzer U. Candida morphogenesis and host-pathogen interactions. Curr Opin Microbiol 2004;7:3507.
  • 32
    Spiegelberg HL. Biological activities of immunoglobulins of different classes and subclasses. Adv Immunol 1974;19:25994.
  • 33
    Costantino PJ, Gare NF, Warmington JR. Humoral Immune-Responses to Systemic Candida-Albicans Infection in Inbred Mouse Strains. Immunol Cell Biol 1995;73:12533.
  • 34
    Boxx GM, Kozel TR, Nishiya CT, Zhang MX. Influence of Mannan and Glucan on Complement Activation and C3 Binding by Candida albicans. Infect Immun 2010;78:12509.
  • 35
    Kozel TR, MacGill RS, Percival A, Zhou Q. Biological activities of naturally occurring antibodies reactive with Candida albicans mannan. Infect Immun 2004;72:20918.
  • 36
    Boxx GM, Nishiya CT, Kozel TR, Zhang MX. Characteristics of Fc-independent human antimannan antibody-mediated alternative pathway initiation of C3 deposition to Candida albicans. Mol Immunol 2009;46:47380.
  • 37
    Caesar-TonThat TC, Cutler JE. A monoclonal antibody to Candida albicans enhances mouse neutrophil candidacidal activity. Infect Immun 1997;65:53547.
  • 38
    Sevilla MJ, Robledo B, Rementeria A, Moragues MD, Ponton J. A fungicidal monoclonal antibody protects against murine invasive candidiasis. Infect Immun 2006;74:30425.